Joseph Echevarria - Pfizer Independent Director

PFE
 Stock
  

USD 51.72  0.06  0.12%   

  Director
Mr. Joseph J. Echevarria is an Independent Director of Pfizer Inc.. Mr. Echevarria was Chief Executive Officer of Deloitte LLP, a global provider of professional services, from 2011 until his retirement in 2014. During his 36year tenure with Deloitte, served in various leadership roles, including Deputy Managing Partner, Southeast Region Audit Managing Partner and U.S. Managing Partner and Chief Operating Officer. Director of The Bank of New York Mellon Corporationrationration, Unum Group, a provider of financial protection benefits, and Xerox Corporationrationration. Member of the Presidents Export Council and former member of the Presidential Commission on Election Administration. Chair Emeritus of My Brothers Keeper Alliance. Member of the Board of Trustees of the University of Miami. Mr. Echevarrias 36year career at Deloitte brings financial expertise and international business, leadership and risk management skills to the Board. Mr. Echevarrias financial acumen, including his significant previous audit experience, expertise in accounting issues and service on the audit committee of another public company, is an asset to Pfizers Board and Audit Committee. Pfizer also benefits from Mr. Echevarrias breadth and diversity of experience, which includes his public service on the Presidents Export Council.
Age: 64  Director Since 2015      
212 733 2323  https://www.pfizer.com
Echevarria was Chief Executive Officer of Deloitte LLP, a global provider of professional services, from 2011 until his retirement in 2014. During his 36year tenure with Deloitte, served in various leadership roles, including Deputy Managing Partner, Southeast Region Audit Managing Partner and U.S. Managing Partner and Chief Operating Officer. Director of The Bank of New York Mellon Corporationrationrationration, Unum Group, a provider of financial protection benefits, and Xerox Corporationrationrationration. Member of the President’s Export Council and former member of the Presidential Commission on Election Administration. Chair Emeritus of My Brother’s Keeper Alliance. Member of the Board of Trustees of the University of Miami.

Joseph Echevarria Latest Insider Activity

Tracking and analyzing the buying and selling activities of Joseph Echevarria against Pfizer stock is an integral part of due diligence when investing in Pfizer. Joseph Echevarria insider activity provides valuable insight into whether Pfizer is net buyers or sellers over its current business cycle. Note, Pfizer insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pfizer'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Pfizer Management Efficiency

Pfizer Inc has Return on Asset of 0.1332 % which means that on every $100 spent on asset, it made $0.1332 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.3551 %, implying that it generated $0.3551 on every 100 dollars invested. Pfizer management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Pfizer Return on Average Assets are projected to increase based on the last few years of reporting. The past year's Return on Average Assets were at 13.09. The current year Return on Average Equity is expected to grow to 33.77, whereas Return on Invested Capital is forecasted to decline to 0.22. Pfizer Current Assets are projected to decrease significantly based on the last few years of reporting. The past year's Current Assets were at 59.69 Billion. The current year Tax Assets is expected to grow to about 5.8 B, whereas Goodwill and Intangible Assets are forecasted to decline to about 84.3 B.
The company has 36.2 B in debt with debt to equity (D/E) ratio of 0.4, which is OK given its current industry classification. Pfizer Inc has a current ratio of 1.56, which is typical for the industry and considered as normal. Debt can assist Pfizer until it has trouble settling it off, either with new capital or with free cash flow. So, Pfizer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pfizer Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pfizer to invest in growth at high rates of return. When we think about Pfizer's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Roxanne AustinVerizon Communications
2020
Mark ParkerWalt Disney
2016
Steven KandarianExxon Mobil Corp
2018
Charles NoskiMicrosoft
2003
James OwensAlcoa Corp
2016
Michael FromanWalt Disney
2018
Suzanne SitherwoodAlcoa Corp
2016
Jeff SmithWalt Disney
2019
Mark McClellanJohnson Johnson
2013
William BrodyInternational Business Machines
2007
Monica LozanoWalt Disney
2000
Wan AriffinExxon Mobil Corp
2021
David FarrInternational Business Machines
2012
Amy AlvingAlcoa Corp
2016
Eugene WashingtonJohnson Johnson
2012
Hubert JolyJohnson Johnson
2019
Charles PrinceJohnson Johnson
2006
William WeldonExxon Mobil Corp
2013
Ian DavisJohnson Johnson
2010
Shirley JacksonInternational Business Machines
2005
Kenneth ChenaultInternational Business Machines
2016
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 79000 people. Pfizer Inc (PFE) is traded on New York Stock Exchange in USA and employs 79,000 people. Pfizer is listed under Pharmaceuticals category by Fama And French industry classification.

Pfizer Inc Leadership Team

Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller
Douglas Lankler, Executive Vice President General Counsel
Shantanu Narayen, Lead Independent Director
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical
Susan DesmondHellmann, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer
Aamir Malik, Executive Vice President Chief Business Innovation Officer
Christopher Stevo, Senior Vice President and Chief Investor Relations Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
William Carapezzi, Executive Vice President - Global Business Services and Transformation
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Mikael MD, Dev Research
James Quincey, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Payal Sahni, Executive Vice President, Chief People Experience Officer
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President - Pfizer Biopharmaceuticals Group
Mike Mcdermott, Executive Vice President Chief Global Supply Officer
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
John Young, Group President - Pfizer Innovative Health and Angela Hwang
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
James Smith, Independent Director
Christopher CFA, VP Officer
Dennis Ausiello, Independent Director
Michael Mcdermott, Executive Vice President Chief Global Supply Officer
Frances Fergusson, Independent Director
Gordon Loh, Senior Vice President Corporate Audit
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
David Denton, Chief VP
Alexander Mackenzie, Executive Vice President Chief Development Officer
DVM DVM, Chairman CEO
William Gray, Independent Director
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Susan Hockfield, Independent Director
Freda LewisHall, Executive Vice President Chief Medical Officer
Dan Littman, Independent Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
Joseph Echevarria, Independent Director
Scott Gottlieb, Independent Director
Ronald Blaylock, Independent Director
Michael Goettler, Group President - Pfizer Upjohn

Pfizer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Pfizer without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Balance Of Power Now

   

Balance Of Power

Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
All  Next Launch Module

Currently Active Assets on Macroaxis

Please check Your Equity Center. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.055
Market Capitalization
290.7 B
Quarterly Revenue Growth YOY
(0.06) 
Return On Assets
0.1332
Return On Equity
0.3551
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.